A roadmap for improving representation in clinical trials

IF 1.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Contemporary Clinical Trials Communications Pub Date : 2024-09-23 DOI:10.1016/j.conctc.2024.101374

Amanda F. Petrik , Nora B. Henrikson , Gloria D. Coronado , Erin Keast , Matthew P. Banegas

引用次数: 0

Abstract

Clinical trials continue to struggle with recruiting diverse participants that include historically underrepresented and minoritized patients, who are typically patients in non-white racial and ethnic groups and have low income (Medicaid). Enrolling diverse participants will benefit the health sciences by providing more generalizable findings. The Cancer Financial Experience project (CAFÉ) study sought to improve financial distress by providing financial navigation for newly diagnosed cancer patients, and intentionally recruited diverse participants. All diverse participants consented at slightly higher rates than non-diverse participants (21.3 % vs. 20.1 %). Spanish-speaking patients consented at a much higher rate than non-Spanish speakers (36.4 % vs. 20.2 % respectively). Here we discuss how we increased our recruitment of diverse participants. Obtaining diverse participation is achievable and will provide more meaningful findings.

查看原文本刊更多论文

提高临床试验代表性的路线图

临床试验在招募多元化参与者方面仍有困难，这些参与者包括历来代表性不足的少数群体患者，他们通常是非白人种族和民族群体的患者以及低收入者（医疗补助）。招募多样化的参与者将有利于健康科学的发展，提供更具普遍性的研究结果。癌症财务体验项目（CAFÉ）研究旨在通过为新诊断的癌症患者提供财务指导来改善财务困境，并有意招募了不同的参与者。所有多元化参与者的同意率略高于非多元化参与者（21.3% 对 20.1%）。西班牙语患者的同意率远远高于非西班牙语患者（分别为 36.4% 对 20.2%）。在此，我们将讨论如何增加对不同参与者的招募。多元化参与是可以实现的，并将提供更有意义的研究结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Contemporary Clinical Trials Communications Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

2.70

自引率

6.70%

发文量

146

审稿时长

20 weeks

期刊介绍： Contemporary Clinical Trials Communications is an international peer reviewed open access journal that publishes articles pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from a wide range of disciplines including medicine, life science, pharmaceutical science, biostatistics, epidemiology, computer science, management science, behavioral science, and bioethics. Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions. Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.